牌照 · 2026-01-13

SFC Listing Committee Approval Process: Decision-Making Mechanism for New Listing Applications

The Hong Kong Exchange (HKEX) Listing Committee is not a rubber stamp. In 2025, the Committee rejected 14% of new listing applications at the initial vetting stage, a rate 40% higher than the 2023 average of 10%, according to HKEX’s own Quarterly Listing Statistics (Q1 2025). This sharp increase follows the SFC’s December 2024 Policy Statement on Listing Vetting, which directed the Committee to apply stricter scrutiny to financial projections, connected transactions, and corporate governance structures of applicants from emerging sectors, particularly biotech and special purpose acquisition companies (SPACs). For any firm planning a Hong Kong IPO in 2026, understanding the Committee’s decision-making mechanism is no longer optional – it is the difference between a successful listing and a costly withdrawal.

The Listing Committee does not review an application until the sponsor has completed a mandatory due diligence period. The HKEX Listing Rules (Chapter 9, Rule 9.11) require a minimum of 12 weeks of sponsor-led work before the formal A1 filing. This period is non-waivable.

The clock starts when the sponsor is formally appointed. The sponsor must submit a Sponsor Declaration (Form A) confirming that it has reviewed the applicant’s business model, financial records, and legal compliance for at least 12 consecutive weeks. If the sponsor identifies material deficiencies – such as incomplete audit trails or unresolved regulatory queries from the SFC – the clock resets. The Committee will not accept a late declaration.

The Pre-Vetting Checklist

Before the A1 filing, the applicant must satisfy five pre-vetting criteria under HKEX Listing Rule 9.03:

Financial Eligibility: Meet one of the three profit tests (profit test, market capitalisation/revenue test, or market capitalisation/revenue/cash flow test) as set out in Rule 8.05.
Management Continuity: At least three consecutive financial years of management continuity (Rule 8.05A).
Ownership Continuity: At least one financial year of ownership continuity (Rule 8.05B).
Sufficiency of Working Capital: A working capital statement covering at least 12 months from the date of the listing document (Rule 8.21A).
Connected Transactions: Full disclosure of all connected transactions, with independent financial advice if the transaction value exceeds 5% of the applicant’s market capitalisation (Chapter 14A).

Failure to meet any one of these criteria at the pre-filing stage results in an automatic deferral. In 2025, 22% of all pre-filing reviews ended in a deferral, per HKEX’s internal data published in its 2025 Annual Report.

Step 2: The A1 Filing and Committee Review Process

Once the sponsor submits the A1 application, the Listing Committee begins its formal review. The process is divided into three phases: initial screening, substantive review, and the listing hearing.

Phase 1: Initial Screening (Days 1–14)

The Committee’s Listing Division conducts a preliminary review within 14 business days. The Division checks for completeness against the A1 checklist. Common reasons for rejection at this stage include:

Missing or unsigned sponsor declarations.
Incomplete financial statements (e.g., no auditor’s report for the most recent financial year).
Failure to disclose all connected transactions.

If the application is incomplete, the Division issues a “Returned Application” notice. The applicant must re-file, restarting the 14-day clock. In 2024, 18% of A1 applications were returned at this stage, according to HKEX data.

Phase 2: Substantive Review (Days 15–60)

The Committee’s substantive review focuses on three core areas:

Financial Projections: The Committee tests the reasonableness of revenue and profit forecasts against industry benchmarks. For biotech applicants, the Committee requires a detailed pipeline analysis and a clear path to commercialisation. The SFC’s 2024 Policy Statement explicitly warns against “aggressive” projections that exceed historical growth rates by more than 50%.
Corporate Governance: The Committee assesses board composition, independence of non-executive directors, and the adequacy of internal controls. For SPACs, the Committee requires a minimum of three independent directors with relevant industry experience (HKEX Listing Rule 18B.35).
Connected Transactions: Any transaction with a connected person valued at over HK$10 million requires a fairness opinion from an independent financial adviser. The Committee may request a second opinion if the transaction is complex.

The Committee may issue one or more “Comment Letters” during this phase. Each letter sets a 14-day deadline for the applicant to respond. Failure to respond results in an automatic suspension of the application.

Phase 3: The Listing Hearing (Day 61+)

The listing hearing is a closed-door session with at least three Committee members. The applicant’s sponsor and legal counsel present the case. The Committee may ask questions on any matter from the A1 application. The hearing typically lasts 60 to 90 minutes.

The Committee has three possible outcomes:

Approval: The application proceeds to the listing stage.
Conditional Approval: The Committee imposes conditions, such as additional disclosure in the prospectus or a delay in the listing date.
Rejection: The Committee issues a written decision with reasons. The applicant may appeal to the Listing Committee’s Appeals Panel within 14 days (HKEX Listing Rule 2A.10).

In 2025, the Committee approved 72% of applications that reached the hearing stage, conditional approval was given to 18%, and outright rejection occurred in 10% of cases, per HKEX’s 2025 Listing Statistics.

Step 3: Post-Approval Compliance and Ongoing Obligations

Approval is not the end. The HKEX Listing Rules impose continuous obligations on listed issuers.

Continuous Disclosure

Under HKEX Listing Rule 13.09, an issuer must disclose any information that is “reasonably expected” to affect the price of its securities. This includes material changes in financial condition, legal proceedings, and changes in directors. The SFC’s 2025 Enforcement Report noted a 30% increase in enforcement actions for late or incomplete disclosure compared to 2024.

Connected Transaction Monitoring

Any connected transaction exceeding 5% of the issuer’s market capitalisation after listing requires shareholder approval. The issuer must also file a quarterly connected transaction report with the HKEX (Rule 14A.55).

The SFC conducts an annual review of sponsor performance. In 2025, the SFC issued formal warnings to three sponsors for inadequate due diligence. A sponsor that receives two warnings in a 12-month period may be suspended from acting as a sponsor for six months (SFC Code of Conduct, paragraph 17.6).

Step 4: Appeal and Re-Application Options

A rejected application is not the end of the road. The applicant has two options.

Appeal to the Listing Committee Appeals Panel

The applicant must file a notice of appeal within 14 days of the rejection decision. The Appeals Panel consists of five members who did not sit on the original Committee. The Panel reviews the decision de novo, meaning it can overturn the original decision entirely. In 2025, the Appeals Panel overturned 8% of original rejection decisions, according to HKEX data.

Re-Application After a Cooling-Off Period

If the applicant chooses not to appeal, it must wait 12 months before re-filing. The cooling-off period is mandatory under HKEX Listing Rule 9.12. During this period, the applicant must address all deficiencies identified by the Committee. A re-application that does not materially change the original application will be summarily rejected.

Practical Takeaways for 2026 Applicants

Start sponsor due diligence at least 16 weeks before the intended A1 filing date – the 12-week minimum is a floor, not a target, and the Committee expects a thorough, documented process.
Prepare financial projections that do not exceed historical growth by more than 50% – the SFC’s 2024 Policy Statement makes this a de facto ceiling for acceptable projections.
Disclose all connected transactions, even those below the 5% threshold, in the A1 application – the Committee may request additional information if it suspects undisclosed relationships.
Engage an independent financial adviser for any connected transaction valued at over HK$10 million – the Committee will not accept a sponsor’s internal fairness opinion as sufficient.
Build a compliance team internally before the listing hearing – post-listing continuous obligations require dedicated resources for disclosure and connected transaction monitoring.

This does not constitute legal advice. Consult a solicitor for your specific case.